Silence Therapeutics Plc Stock Price, News & Analysis

SLN360 demonstrated a significant reduction in lipoprotein(a) (Lp(a)), a key genetic risk factor for heart disease, with reductions of up to 98% observed in the phase 1 APOLLO trial. Results showed that reductions of up to 81% persisted at 150 days. These findings, published in The Journal of the American Medical Association, support the further development of SLN360, which targets Lp(a) production. The study involved 32 adults and reported no serious safety concerns. Silence Therapeutics plans to advance SLN360 into phase 2 trials focused on patients with cardiovascular disease.

Silence Therapeutics has announced the filing of a clinical trial application (CTA) for SLN501, an siRNA therapy targeting complement C3, triggering a $3 million milestone payment from Mallinckrodt. The Phase 1 study is anticipated to commence in the first half of 2022. This collaboration, initiated in July 2019, includes a total of $2 billion in potential milestone payments and tiered royalties on sales. Silence aims to leverage its mRNAi GOLD™ platform to address unmet medical needs in complement-mediated diseases.

Silence Therapeutics plc (SLN) reported notable progress in 2021, including advancements in its mRNAi GOLD™ platform and successful enrollment in key clinical studies. The company achieved positive topline results for SLN360, with a significant Lp(a) reduction, and expects to present detailed data at the ACC Annual Meeting on April 3, 2022. Financially, Silence recognized £12.4 million in revenue for the year, a substantial increase from £5.5 million in 2020, despite a net loss of £39.4 million due to rising R&D costs. The company ended 2021 with £73.5 million in cash, adequate to sustain operations into early 2023.

Silence Therapeutics plc, trading as SLN on Nasdaq, announced it will release its financial and business results for Q4 and the full year ending December 31, 2021 on March 17, 2022. A conference call will take place at 8:00 a.m. EDT (12:00 p.m. GMT) on the same day, offering insights into the Company’s performance and updates. Investors can access the live webcast via the Company’s website. Silence specializes in developing siRNA therapeutics targeting diseases with unmet medical needs, including cardiovascular and hematological conditions.

Silence Therapeutics plc (NASDAQ: SLN) has announced a leadership change, appointing Craig Tooman as President and CEO, succeeding Mark Rothera, who steps down immediately. Rhonda Hellums takes over as CFO. Tooman brings over 30 years of experience, including previous roles at Vyome Therapeutics and Aratana Therapeutics. Iain Ross, Chairman, expressed confidence in Tooman’s ability to enhance the company's strategy and leverage positive clinical data from SLN360 to ensure long-term shareholder value.

Silence Therapeutics announced positive results from the phase 1 single-ascending dose study of SLN360, an investigational siRNA for lowering lipoprotein(a) (Lp(a)).

SLN360 demonstrated a significant reduction in Lp(a) by up to 98%, with reductions of up to 81% lasting for 150 days. The study involved 32 adults with high Lp(a) and showed no major safety concerns. Results will be presented at the American College of Cardiology Scientific Session on April 3, 2022.

Silence plans to initiate a phase 2 study in patients with stable atherosclerotic cardiovascular disease in the second half of 2022.

Silence Therapeutics, a leader in siRNA therapeutics, announced that a late-breaking clinical abstract on the SLN360 phase 1 study will be presented at the ACC Annual Scientific Session on April 3, 2022. This study focuses on healthy volunteers with high lipoprotein(a) levels. Topline data from this study is set to be reported this quarter. The principal investigator, Dr. Steven Nissen from the Cleveland Clinic, will present detailed results during the session, highlighting the study's significance in addressing cardiovascular risk.

Silence Therapeutics plc (Nasdaq: SLN) has announced that Dr. Marie Wikström Lindholm has been elected to the Board of Directors of the Oligonucleotide Therapeutics Society for a two-year term. This appointment underscores her significant contributions to the field of oligonucleotide therapeutics and is expected to enhance the company's reputation in scientific excellence. Dr. Lindholm has been with Silence since December 2017, playing a critical role in optimizing their proprietary mRNAi GOLD™ platform aimed at treating diseases with high unmet medical needs.

Silence Therapeutics (Nasdaq: SLN) announced its participation in the H.C. Wainwright BioConnect Virtual Conference scheduled for January 10-13, 2022. The company will feature in a fireside chat, with an on-demand presentation available from January 10 at 7:00 AM ET / 12:00 PM GMT via its Investors section on the Silence website. This engagement highlights Silence's commitment to addressing unmet medical needs through innovative siRNA therapeutics, including SLN360 for cardiovascular risk and SLN124 for rare hematological diseases.